Genmab A/S
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GMAB | SMMT | LEGN | ROIV | BNTX | IDYA | |
|---|---|---|---|---|---|---|
| Market cap | 22.98B | 13.67B | 3.46B | 24.99B | 24.08B | 3.48B |
| P/E (TTM) | 29.4 | — | — | — | — | — |
| Forward P/E | 24.5 | -15.0 | 17.0 | -20.1 | -17.5 | -9.0 |
| Price/book | 3.7 | 21.6 | 2.8 | 5.9 | 1.2 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +13.43% | −23.29% | −43.32% | +118.63% | −6.60% | +34.89% |
| Today | +0.81% | −2.62% | −4.40% | −2.40% | −1.16% | −0.14% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GMAB news ›Genmab A/S (NASDAQ:GMAB) Given New $50.00 Price Target at HC Wainwright
Genmab A/S (NASDAQ:GMAB – Get Free Report) had its price objective increased by stock analysts at HC Wainwright from $40.00 to $50.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy”…
Genmab A/S reports 51% lower progression or death risk in Phase 3 lymphoma trial
The primary IPI 3 to 5 cohort showed a 0.49 hazard ratio, while the partners plan regulatory talks without a stated filing date. A 51 per cent reduction in the risk of progression or death emerged from a Phase 3 first-line lymphoma trial…
Genmab A/S Stock 12‑Month Price Target Raised to $42, Implies 9% Upside
TradingView Genmab A/S Stock 12‑Month Price Target Raised to $42, Implies 9% Upside - According to estimates from 21 analysts, Genmab A/S stock's average price target has risen from $41.45 to $42, with forecasts ranging from $30.93 to $58…
Genmab A/S Stock (GMAB) Moved Up by 13.01% on Oct 5: Key Drivers Unveiled
TradingKey Genmab A/S Stock (GMAB) Moved Up by 13.01% on Oct 5: Key Drivers Unveiled What is driving Genmab A/S (GMAB)’s stock price up today? Genmab experienced strong upward momentum following significant clinical pipeline breakthroughs…
Genmab A/S (NASDAQ:GMAB) versus Arvinas (NASDAQ:ARVN) Financial Survey
Posted by Defense World Staff on Oct 5th, 2026 Arvinas (NASDAQ:ARVN – Get Free Report) and Genmab A/S (NASDAQ:GMAB – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses…
Genmab A/S reports 45.9% Rina‑S response in ovarian cancer trial
Among 109 treated patients, the median response lasted 12.1 months; the single-arm cohort offers no direct efficacy comparison. A 45.9 per cent confirmed tumour response rate has given Genmab A/S NASDAQGMAB fresh evidence for its ovarian…
[6-K] GENMAB A/S Current Report (Foreign Issuer)
Genmab A/S (GMAB) is a Copenhagen-based biotechnology company developing antibody medicines and platforms for cancer and serious diseases worldwide. [6-K] GENMAB A/S Current Report (Foreign Issuer) Sentiment and the balance of points…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
defenseworld.net2
-
tradingview.com2
-
mugglehead.com1
-
stocktitan.net1
-
tradingkey.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.